Background: Glucose transporter 1 (GLUT1) plays a critical role in tumorigenesis and tumor progression in multiple cancer types. However, the specific function and clinical significance of GLUT1 in prostate cancer (PCa) are still unclear. Therefore, in this study, we investigated the role of GLUT1 in PCa.
Methods: GLUT1 protein levels in prostate cancer tissue and tumor-adjacent normal tissues were measured and compared. Furthermore, real-time PCR and Western blot analysis were both used to detect GLUT1 expression levels in different PCa cell lines.
Flow cytometry and cell-based assays, such as a glucose uptake and lactate secretion assay, CCK-8 assay, and transwell migration and wound healing assay, were used to monitor cancer cell cycle distribution, glycolysis, proliferation, and motility, respectively. Moreover, a mouse tumor xenograft model was used to investigate the role of GLUT1 in tumor progression in vivo.
Results: GLUT1 expression levels are higher in PCa tissues than in tumor-adjacent normal tissues. The results from real-time PCR and Western blot analysis revealed a similar increase in the GLUT1 expression levels in PCa cell lines. Moreover, knockdown of GLUT1 inhibits cell glycolysis and proliferation and leads to cell cycle arrest at G2/M phase in the 22RV1 cell line but not in the PC3 cell line. In vivo experiments further confirmed that GLUT1 knockdown inhibits the growth of tumors derived from the 22RV1 cell line. In addition, we also showed that GLUT1 knockdown has no effect on cell migration in vitro.
Conclusions: GLUT1 may play an important role in PCa progression via mediating glycolysis and proliferation. Our study also indicated a potential crosstalk between GLUT1-mediated glycolysis and androgen sensitivity in PCa. The most recent national statistics have shown that the incidence of PCa is continuously increasing in China. 2 Although PCa treatments, such as androgen deprivation therapy, radical prostatectomy, and radiation therapy, have significantly increased the patient survival rate, [3] [4] [5] the development of castration resistance and metastasis Hengjun Xiao and Jun Wang contributed equally to this work.
greatly limit therapeutic efficacy and overall survival. 6 Therefore, it is urgent to find new potential therapeutic targets of PCa.
Glucose transporter 1 (GLUT1) is a member of the glucose transporter family and regulates glucose transport across the cell membrane. 7 Glucose transmembrane transport is not only the ratelimiting step of glycolysis but also the first step of glucose metabolism. the GLUT1 mRNA and protein levels were found to be higher in PCa in vitro. 9 Moreover, recent study also found that GLUT1 levels increased significantly in proliferative intraductal PCa, 10 and the expression level of GLUT1 in Gleason pattern 4 (GP4) PCa tissues was higher than that in Gleason pattern 3 (GP3) PCa tissues. 11 Therefore, new studies are needed to resolve these controversial findings.
In addition, numerous studies have shown that GLUT1 plays a key role in multiple cancer types, such as hepatocellular, breast, and renal cancer, by promoting cell proliferation and metastasis and inhibiting apoptosis. [12] [13] [14] However, whether GLUT1 plays a key role in PCa has yet to be elucidated. In this study, we showed that the GLUT1 expression level is considerably higher in PCa tissues than in tumoradjacent normal tissues. In addition, our results also suggested that GLUT1 knockdown inhibits glycolytic activity and cell proliferation in vitro and in vivo. Informed consent was obtained from all participants.
| Immunohistochemistry
A Leica Autostainer XL ST5010 (Leica Biosystems, Wetzlar, Germany) was used to visualize GLUT1 immunoreactivities. The tissue sections were deparaffinized and quenched to block endogenous peroxidase activity and were then incubated with 1% bovine serum albumin (BSA) in PBS for 1 h. Then, the slides were incubated with a rabbit monoclonal anti-GLUT1
antibody (Abcam, ab115730, 1:500) or rabbit polyclonal anti-Ki-67
antibody (Cell Signaling, #9129, 1:300) overnight at 4°C in a humidified chamber, followed by incubation with secondary antibodies for 30 min. final IHC score was determined by multiplying the intensity score and the positivity score to achieve a final score ranging from 0 to 12. Samples with an IHC score of more than 3 were considered positive, and samples with a score less than 3 were considered negative.
| Cell culture
The human prostate cancer cell lines, PC3, DU145, LNCap, and 22RV1, and the prostate epithelial cell line RWPE-1 were purchased from the 
| Western blot analysis
Total protein was extracted from cells using RIPA lysis buffer (KeyGENBioTECH, Nanjing, China) according to the manufacturer's instructions, and the protein concentration was quantified using a bicinchoninic acid (BCA) protein assay kit (KeyGENBioTECH, Nanjing, China). The cell lysate was resolved by 10% sodium dodecyl sulfate- | 87
Finally, the protein was visualized using ECL plus Western blot detection reagents (KeyGENBioTECH, Nanjing, China).
| Small interfering RNA (siRNA) construction and transfection
The siRNA targeting GLUT1 was designed and synthesized by RiboBio (Guangzhou, China) and the sequence is 5′-GCATGTGCTTCCAGTATGT-3′.
Cells were transfected with the oligonucleotide using Lipofectamine 2000
(Invitrogen LifeTechnologies, CA) following the manufacturer's instructions.
The siRNA was used at a concentration of 100 nM.
| Detection of the levels of glucose uptake and lactate secretion
Concentrations of glucose and lactate in the media were respectively detected with a Glucose Colorimetric Assay Kit (BioVision, CA) and a Lactate
Assay Kit (BioVision, CA) according to the manufacturer's instructions. 15 
| Cell viability assay

| Flow cytometry (FCM)
FCM was used to analyze the cell cycle distribution of the 22RV1 and PC3 cell lines transfected with GLUT1 siRNA or control. Cells were resuspended and incubated in 500 µL PBS (1%, pH 7) containing PI (50 µg/mL) and RNase A (100 µg/mL)for 15 min in the dark. A minimum of 10,000 events was collected for FCM analysis. Experiments were repeated at least three times. 5′-AATACCCTGGAACAGGCAGATA-3′. The PCR products were denatured and rehybridized and were then treated with T7E1 endonuclease.
| In vitro migration and wound healing assays
Finally, the PCR products were resolved on an agarose gel.
| Generation of GLUT1-knockout cells by CRISPR/Cas9
We transfected HEK293T cells with lentiCRISPRv2-gRNA, psPAX2 and 
| Statistical analysis
All data are presented as the mean ± standard deviation (SD Figures 1A and 1B) . Clinical parameters are shown in Table 1 . The IHC scores of the 65 pairs of PCa tissues and tumor-adjacent normal tissues were 5.53 ± 3.74 and 3.36 ± 2.27, respectively, and the difference between the two tissue types was statistically significant ( Figure 1C) . By analyzing the relationship between GLUT1 expression levels in PCa and clinical parameters, we found that GLUT1 has higher expression in groups with a Gleason score >7 ( Figure 1F ) than in groups with a Gleason score <7 or =7 ( Figures 1D and 1E , χ2 = 9.302, P < 0.05).
In addition, GLUT1 expression was higher in groups with a PSA level of more than 20 ng/mL than in groups with a lower PSA level (χ2 = 5.747, P < 0.05). However, the GLUT1 expression level did not significantly correlate with other parameters such as age, tumor size, and pathological staging (Table1).
| GLUT1 expression levels are higher in prostate cancer cells
To further explore the expression levels of GLUT1 and how GLUT1
regulates the biological behaviors of prostate cancer, we first used qPCR and Western blot analysis to detect the mRNA and protein levels of GLUT1 in normal prostate epithelial cell line RWPE-1 and the PCa cell lines PC3, DU145, 22RV1, and LNCap. As shown in Figure 2A , the mRNA expression level of GLUT1 in the prostate cancer cell lines was higher than that in the prostate normal epithelial cell RWPE-1. Moreover, Western Figures 2B and 2C ).
| Downregulated GLUT1 expression suppresses glycolysis in 22RV1 cells
Considering GLUT1 is a key protein that regulates cell glycolysis, we further explored the effects of GLUT1 knockdown on glycolysis in prostate cancer cells. The ability of cells to conduct glycolysis was tested by detecting glucose uptake and lactate secretion of different cell lines. Compared with the control group, the glucose intake and lactic acid secretion capacity of 22RV1 were significantly reduced after GLUT1 siRNA transfection ( Figures 3A and 3B ), and the difference was statistically significant. However, there were no significant changes in glucose uptake and lactate secretion in PC3 cells with or without GLUT1 knockdown ( Figures 3C and 3D ).
| Downregulation of GLUT1 expression suppresses cell proliferation and meditates G2/M phase arrest in 22RV1 cells
To explore the role of GLUT1 in cell proliferation, we used the CCK-8 assay to investigate the proliferation rate of cells transfected with siRNA or negative control. We found no significant differences between siRNA-transfected and negative control groups in PC3 cells ( Figure 4A ). However, 48 h after siRNA transfection, 22RV1 cells showed significantly decreased OD values, which indicated a significant inhibition of proliferation in 22RV1 cells (P < 0.05, Figure 4B ). Moreover, after siRNA transfection, there was no significant difference between the ability of PC3 cells and the negative control group to progress through the cell cycle ( Figures 4C and 4D ).
However, downregulation of GLUT1 expression in 22RV1 cells, compared with the control group, led to a significant increase in G2/M phase arrest and led to a reduction in the G0/G1 cell population ( Figures 4E and 4F , P < 0.01).
3.5 | Downregulation of GLUT1 expression has no effect on PCa cell invasion and metastasis
We examined the invasion ability of different cell lines by transwell and wound healing assay to explore the role of GLUT1 in cell invasion. The results showed that the number of migrating 22RV1 and PC3 cells was not significantly affected after siRNA transfection. In addition, the wound healing assay showed no obvious difference between the siRNA group and the control group, as shown in Supplementary Figure. 3.6 | GLUT1 knockout inhibits 22RV1 cell-derived tumor growth in a nude mouse xenograft model
To further explore the impact of GLUT1 on the growth of the 22RV1 cell line and PC3 cell line in vivo, we employed a CRISPR-CAS9 system to construct GLUT1 gene knockout models of 22RV1 and PC3 cells.
Confirmed by T7E1 assay (Figure 5A ), gene knockout cells and negative control cells were then subcutaneously injected into the nude mice. Forty-five days after implantation, the mice were euthanized and the tumors were removed. As shown in Figure 5B -F, while GLUT1 knockout resulted in a marked reduction in tumor volume and weight in the 22RV1-derived tumor mouse model (P < 0.05), no significant differences in the tumor volume and weight were observed in the 
| DISCUSSION
Cancer cells prefer glycolysis rather than mitochondrial respiration regardless of the presence of oxygen. 16 This unique metabolic characteristic of cancer is known as aerobic glycolysis and has been considered a potential target for the development of new therapies. 17, 18 However, studies have found that glycolysis is not as active in PCa as it is in liver or lung cancer. 15 A recent study found that a key glycolytic enzyme GLUT1 is an independent predictor that significantly correlates with a shorter time to biochemical recurrence in PCa. 19 However, the function of GLUT1 in PCa cells has not been fully elucidated. Therefore, studies exploring the clinical significance function and mechanisms of GLUT1 in PCa may lead to a breakthrough in the diagnosis and treatment of PCa.
Researchers have found that GLUT1 is upregulated and associated with shorter overall survival in lung and pancreatic cancer. 20 Although it was reported that the expression of GLUT1 is increased in intraductal PCa, further characterization of GLUT1 will deepen our understanding of its role in the occurrence and progression of PCa. Our results
showed that the levels of GLUT1 expression were upregulated in PCa tissues compared to tumor-adjacent normal tissues and were associated with the PSA level and Gleason score but independent of tumor stage and size. Taken together, our study is in favor of the view that GLUT1 is upregulated in PCa but not involved in PCa progression, which may indicate the limited prognostic value of GLUT1.
The expression of GLUT1 is regulated by many factors, such as serine/threonine kinase Akt1 and PI3 signaling, with the most important factor being hypoxia and the transcription factor hypoxiainducible factor 1 (HIF-1). [21] [22] Studies focused on the function of GLUT1 in tumors showed that GLUT1 promotes proliferation and metastasis and inhibits apoptosis in several cancer types, such as lung cancer and breast cancer. [23] [24] [25] Nevertheless, the expression and function of GLUT1 in PCa cell lines have yet to be clarified. In our study, the mRNA and protein levels of GLUT1 in PCa cell lines are all higher than that in the normal prostate epithelial cell line RWPE-1.
To further investigate the function of GLUT1 in PCa cell lines, we knocked down GLUT1 in the PCa cell lines PC3 and 22RV1 by siRNA transfection. In 22RV1 cells, GLUT1 knockdown led to reduced proliferation and glycolysis rates and cell cycle arrest in G2/M phase.
However, in PC3 cell, GLUT1 knockdown did not significantly affect proliferation, glycolysis or the cell cycle. In addition, downregulated expression of GLUT1 had no effect on invasion capacity in either 22RV1 or PC3 cells. Moreover, using the CIRISR-CAS9 system, we constructed GLUT1 stable knockout 22RV1 and PC3 cell and then subcutaneously injected these cells into nude mice. We found that another study showed that androgen upregulates the expression of GLUT1 in androgen-responsive LNCaP cells but had no effect on the regulation of GLUT1 expression in nonresponsive PC3 and DU145 cells. 29 In general, previous studies demonstrated that the different roles of GLUT1 in different PCa cell lines may be attributed to different responsiveness to androgen. Our study showed GLUT1-regulated cell proliferation and glycolysis in androgen-responsive 22RV1 cells, but its specific mechanisms and relationship with androgen and androgen receptor still need further studies.
There were a number of limitations in our study. For example, follow-up data of the PCa patients are absent in this study, and thus we could not investigate the prognostic significance of GLUT1. In addition, our samples were collected from a single-center trial; as such, large samples and multi-center clinical trials will further validate the relationship between GLUT1 expression and clinical features. Lastly, the detailed relationship between the role of GLUT1 and androgen sensitivity in PCa remains elusive. Further work on this question may bring new ideas and strategies to the diagnosis and treatment of PCa.
